EQS-News
SYNBIOTIC acquires Ilesol: Enormous competitive advantages through cannabinoid extracts and isolates from own production - Seite 2
"As part of the SYNBIOTIC group of companies, we can take the next steps together on a European level. As an experienced manufacturer with independent, technologically mature production processes, we will be an absolute asset to everyone involved in SYNBIOTIC in every respect," explains Sasha Bajilo, CEO and Co-Founder, Ilesol Pharmaceuticals.
The declared aim of CEO Daniel Kruse is to establish SYNBIOTIC as the leading group of companies for industrial hemp and cannabis not only on the German market, but also on the European market. With the acquisitions of Bushdoctor and Ilesol, SYNBIOTIC is now also active in Austria and Croatia.
"The Group's pan-European orientation is the logical step towards a strong market position throughout Europe. This not only completes our supply chain and increases our sales potential, but also increases SYNBIOTIC's importance for large, strategic investors from outside Europe," says Kruse.
About Ilesol Pharmaceuticals
Ilesol Pharmaceuticals is an industrial manufacturer of cannabinoid extracts and CBD isolates specialising in cosmetic ingredients, cosmetic products and dietary supplements. The company, based in Varaždin /Croatia, has its own production facility with an area of 3,400 metres2 and covers the entire production process.
Publisher
SYNBIOTIC SE
Daniel Kruse
Managing Director
Münsterstrasse 336
40470 Düsseldorf
Germany
Media contact
Rüdiger Tillmann
SYNBIOTIC
Public Relations Manager
E-mail ruediger.tillmann@synbiotic.com
Mobile +49 171 3677028
c/o JOLE.group
About SYNBIOTIC
SYNBIOTIC is a listed group of companies in the hemp and cannabis sector and pursues a buy and build investment strategy focussed on the EU. The group covers the entire value chain from cultivation to production and retail - from the field to the shelf. The core businesses of the vertically integrated company are research and development, production and commercialisation of hemp, CBD and cannabis products.
SYNBIOTIC has a clear strategy to further expand along the value chains of its business areas - hemp and CBD, medical cannabis and consumer cannabis.
23.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
Lesen Sie auch
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte